A Phase 3 interventional study of Tofacitinib in Ankylosing Spondylitis, sponsored by Pfizer. Completed at 99 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 32nd registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 129 across the 18 interventional studies, 276 across the 16 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib
Drug: Tofacitinib
Oral administration twice per day
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16
ASAS20 assess 4 domains: Patient Global Assessment of Disease (PGA) (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Question \[Q\]5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: greater than or equal to (\>=) 20 percent (%) improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.
Time frame: Week 16
Percentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 16
ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.
Time frame: Week 16
Number of Participants With Treatment Emergent Adverse Events (AEs)
An AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent were events between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to Week 16 and Baseline up to Week 48
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
AE: any untoward medical occurrence in subject who receive study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events that occurred between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state. The severity grades (mild, moderate and severe) were defined as - mild: did not interfere with participant's usual function, moderate: Interfered to some extent with participant's usual function and severe: Interfered significantly with participant's usual function.
Time frame: Baseline up to Week 16 and Baseline up to Week 48
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Hematology (Hemoglobin, Hematocrit, Erythrocyte, Lymphocyte/Leukocyte, Neutrophil/Leukocyte \<0.8\*Lower limit of normal (LLN), Reticulocyte \>1.5\*Upper limit of normal (ULN), Erythrocyte Mean Corpuscular Volume, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular HGB Concentration \<0.9\*LLN, \>1.1\*ULN, Reticulocyte/Erythrocyte, Leukocyte \>1.5\*ULN, Lymphocyte, Neutrophil \<0.8\*LLN and \>1.2\*ULN, Basophil, Basophil/Leukocyte, Eosinophil, Eosinophil/Leukocyte, Monocyte, Monocyte/Leukocyte \>1.2\*ULN); Clinical Chemistry (Bilirubin, Glucose \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase \>3.0\*ULN, Urea, Creatinine, Triglyceride, Cholesterol \>1.3\*ULN, LDL Cholesterol\>1.2\*ULN, Potassium, C Reactive Protein \>1.1\*ULN, Bicarbonate \<0.9\*LLN, Creatine Kinase \>2.0\*ULN, HDL Cholesterol \<0.8\*LLN), Urinalysis (Specific Gravity \>1.035, pH \>8, Glucose, Ketones, Protein, Hemoglobin \>=1, Erythrocyte, Leukocyte \>=20, Granular Cast, Hyaline Cast\>1.
Time frame: Baseline up to Week 16 and Baseline up to Week 48
Number of Participants With Vital Signs Abnormalities
Criteria for abnormalities in vital signs: Pulse rate \<40 beats per minute (bpm) to \>120 bpm, Sitting Diastolic blood pressure \< 50 millimeter of mercury (mmHg), increase and decrease in change from baseline of \>= 20mmHg, sitting systolic blood pressure \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg.
Time frame: Baseline up to Week 16 and Baseline up to Week 48
Number of Participants With Abnormalities in Physical Examination
Complete physical examination: included general appearance, skin (presence of rash), heent (head, eyes, ears, nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), lower extremities (presence of peripheral edema), abdominal (palpation and auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Abnormalities in physical examination was based on investigator's discretion/clinical judgement.
Time frame: Screening, Week 16, and Week 48
Number of Participants With Electrocardiogram (ECG) Abnormalities
Twelve-lead electrocardiograms (ECGs) were obtained for all participants. Criteria for ECG abnormality: PR interval \>=300 and a percent change from baseline of \>=25 or 50%; QRS duration \>=140 and a percent change from baseline of \>=50%; QT interval \>=500; QTCB, QTCF interval \<480 or \>=450, \<500 or \>=480, \>=500, change from baseline of \<60 and \>=30, and change from baseline of \>=60.
Time frame: Baseline up to Week 16, Baseline up to Week 48
Percentage of Participants Achieving ASAS20 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48
ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.
Time frame: Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Percentage of Participants Achieving ASAS40 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48
ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.
Time frame: Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Change From Baseline in Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and calculated by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(high sensitivity \[hs\] CRP mg/Liter \[L\] + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Blood samples were collected for analysis of hsCRP using an assay analyzed by central laboratory. hsCRP is an acute phase reactant, which was indicative of inflammation and of its severity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Weeks 16 and 48
The ASQoL was an 18-item questionnaire assessed the amount of restriction participant experienced in daily activities, level of pain and fatigue, and the impact on the participant's emotional state. Each item was scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranged from 0 (no impact) to 18 (yes-impact), with higher values indicated more impaired health-related quality of life.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Short-Form-36 Health Survey-Version 2 Acute (SF-36v2) Score at Weeks 16 and 48
SF-36 v.2 (Acute): 36-item generic health status measure. It measured 8 general health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, mental health. These domains were aggregated into 2 summary scores - physical component summary (PCS), mental component summary (MCS). Four domains comprised PCS score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised MCS score (vitality, social functioning, role-emotional, mental health). Normalized domain scores, PCS, MCS scores are used in analyses. Component and domain scores were scored by using United States 1998 general population norm. Resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scale and component summary measures had means of 50 and standard deviations of 10. Higher PCS/MCS/domain score represent better health status.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Cervical Rotation Angle at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASMI assess axial status and spinal mobility. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component score mapped between 0 and 10, high score=more impairment of axial status, spinal mobility. For cervical rotation angle, participant sit straight on chair with chin level and hands on knees. Blinded assessor place goniometer at top of head in line with nose and ask participant to rotate neck maximally to left, follows with goniometer and record angle between sagittal plane and new plane after rotation. A second reading obtained and both readings recorded. Procedure repeated for right side. Better of two for each side was selected for scoring. Scoring done by calculating mean of left and right measurement and recorded in degrees (range: 0 to 90), higher cervical rotation value=better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Intermalleolar Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of intermalleolar distances, participant should lie supine with the knees straight and feet/toes pointing straight up and asked to separate the legs as far as possible and the distance between the medial malleoli was measured (in Centimeters \[cm\] to the nearest 0.1 cm). Distance (in cm) was greater than or equal to 0, with no maximum defined range: higher intermalleolar distance value indicates better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lateral Spinal Flexion at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASMI assess axial status, spinal mobility, using linear function. It composed of 5 clinical measures. BASMI - Linear Method score-average of 5 component scores mapped between 0 and 10, with high scores =more impairment of axial status, spinal mobility. For assessment of lateral spinal flexion: participant stand upright with head and back rest against wall as close as possible with shoulders level and feet 30 cm apart and feet parallel. At tip of middle finger, place a mark on thigh. This neutral position recorded. Participant bend sideways without bending knees or lifting heels while attempting to keep shoulders in same position (flexion position). Second mark placed, lateral flexion recorded (left or right as appropriate) using cm tape measure. Two tries for left, two tries for right measured. Result of two tries recorded for left and right separately in cm to nearest 0.1 cm. Distance (in cm) should be \>=0, with no maximum defined range: high value indicates better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lumbar Flexion (Modified Schober) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASMI assessed axial status and spinal mobility. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of lumbar flexion, With the participant standing erect and outer edges of feet 30 cm apart, a mark was placed in the midpoint of a line that joins the posterior superior iliac spines (baseline mark). A second mark (A) was placed 10 cm above the baseline mark and a third mark (B) 5 cm below the baseline mark. Then have the participant maximally bend forward, keeping the knees fully extended. With the participant's spine in full flexion, the distance between marks A and B (in cm to the nearest 0.1 cm) was re-measured. Distance (in cm) was greater than or equal to 0, with no maximum defined range. Higher value indicates better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Tragus-to-wall Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of tragus-to-wall distance, participant was placed standing with his/her back against the wall; knees straight; scapulae, buttocks, and heels against wall; and head in as neutral position as possible. The distance between the tragus and wall in cm was measured (to the nearest 0.1 cm) from both the right side and left side at the maximum effort to touch the head against the wall. Distance should be greater than or equal to 0 cm with no defined maximum value, lower tragus-to-wall value indicates better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Linear Method Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
The BASMI was used to assess the axial status and spinal mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue) and was analyzed using the linear function method. BASMI score composed of five clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation. BASMI - Linear Method score was the average of 5 individual component scores mapped between 0 and 10 and thus the BASMI - Linear Method total score ranged from 0 (very good) to 10 (very poor), wherein higher scores indicated more impairment of axial status and spinal mobility; lower scores indicated better health status.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
FACIT-F is a 13-item questionnaire (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired), with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three type of scores were derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score was calculated by summing the 13 items (range 0 \[not at all\] to 52 \[very much\]); higher scores represent less fatigue status. In this outcome measure, change from baseline in FACIT-F total score was reported.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score was calculated by summing 5 items: I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy. FACIT-F total experience domain score ranged from 0 (not at all) to 20 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F experience domain score was reported.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless, I feel tired, and I have energy, while FACIT-F impact domain score was calculated by summing the remaining 8 items. FACIT-F impact domain score ranged from 0 (not at all) to 32 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F impact domain score was reported.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Patient's Global Assessment of Disease (PGA) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Participants answered the question, "How active was your spondylitis on average during the last week?. Participant's response was recorded using a numerical rating scale ranged from 0 (Not Active) to 10 (Very Active), with higher scores indicated more severe disease.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Patient's Assessment of Spinal Pain: Nocturnal Spinal Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Participants marked their level of nocturnal spinal pain on a NRS ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASFI was a functional index which included 10 items assessing ability of participants to perform normal daily activities. The first 8 questions/items consider activities related to functional anatomy. The final 2 questions/items assess the participants' ability to cope with everyday life. Each item was scored on a scale of 0=easy to 10=impossible. The BASFI total score was calculated as the average score of these 10 individual items. BASFI total score ranged from 0 (easy) to 10 (impossible), where higher scores indicated more severe disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Inflammation (Morning Stiffness) Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI inflammation score was derived by taking mean of the responses of question 5 and 6 and ranged from 0 (none) to 10 (very severe), where higher score indicated more inflammation (morning stiffness).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants Achieving ASAS 5/6 Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants Achieving ASAS Partial Remission at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Partial remission was defined as a score of 2 or less (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains in ASAS. These 4 domains included: PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. BASDAI score was calculated by computing mean of questions 5 and 6 and adding it to sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI50 response was defined as decrease of \>=50% from Baseline in BASDAI score at specified time points. Percentage of participants with BASDAI 50 response at specified weeks are reported.
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Clinically Important Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) clinically important improvement was defined as decrease from Baseline of \>=1.1 units in ASDAS(CRP) score.
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Major Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) major improvement was defined as a response if improvement (decrease) from Baseline in ASDAS(CRP) of \>=2.0 units.
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Inactive Disease Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) inactive disease is defined as a response if actual ASDAS(CRP) was \<1.3 units.
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8, 12, 16, 24, 32, 40 and 48
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Sites assessed included 1st costochondral joint (left \[l\]/right \[r\]), 7th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES score ranging from 0 (no tenderness) to 13 (worst possible score) with higher score indicated more severe tenderness.
Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Swollen Joint Count (SJC) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Swollen joint count was an assessment on 44 joints (sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals, thumb interphalangeal, proximal interphalangeals, knees, ankles, and metatarsophalangeals). Each joint was assessed for swelling as: Present or Absent. Artificial joints were not assessed
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in Spinal Mobility (Chest Expansion ) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Chest expansion (measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion which was defined to be greater than or equal to 0 cm with no defined maximum/upper limit. Greater chest circumference corresponds to higher score indicated more spinal mobility/better health status (measured as Chest Expansion in cm).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Change From Baseline in EuroQol 5 Dimensions 3 Levels (EQ-5D-3L) Score at Weeks 16 and 48
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Participants rated 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The mean of the summed score ranged from 1 to 3 with "1" corresponding to no problems and "3" corresponding to severe problems in the 5 dimensions, where higher score indicates more severe problems.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score (mm) at Weeks 16 and 48
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Its second part included EQ-VAS. EQ-VAS recorded the participant's self-rated health on a VAS ranging from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state), with higher scores indicating better health state.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to Health Problem at Weeks 16 and 48
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent work time missed due to health problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working Due to Health Problem at Weeks 16 and 48
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent Impairment while Working due to Health Problem was a subscale and calculated as: Q5/10 for those who were currently employed and actually worked in the past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment Due to Health Problem at Weeks 16 and 48
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent overall work impairment due to health problem was a subscale and calculated as: Q2/(Q2+Q4)+\[(1- Q2/(Q2+Q4))×(Q5/10)\] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.
Time frame: Baseline, Weeks 16 and 48
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment Due to Health Problem at Weeks 16 and 48
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent activity impairment due to health problem was a subscale and calculated as: Q6/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.
Time frame: Baseline, Weeks 16 and 48
| Milestone | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Started | 134 | 136 |
| Treated | 133 | 136 |
| Completed | 132 | 133 |
| Not completed | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Randomized, but not treated | 1 | 0 |
| Milestone | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Started | 132 | 133 |
| Treated | 132 | 133 |
| Completed | 125 | 127 |
| Not completed | 7 | 6 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
ASAS20 assess 4 domains: Patient Global Assessment of Disease (PGA) (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Question \[Q\]5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: greater than or equal to (\>=) 20 percent (%) improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 | 56.39 | 29.41 |
ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Percentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 16 | 40.60 | 12.50 |
An AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent were events between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Up to Week 16 | 73 | 70 |
| Up to Week 48 | 103 | 93 |
AE: any untoward medical occurrence in subject who receive study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events that occurred between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state. The severity grades (mild, moderate and severe) were defined as - mild: did not interfere with participant's usual function, moderate: Interfered to some extent with participant's usual function and severe: Interfered significantly with participant's usual function.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Up to Week 16: Mild | 53 | 52 |
| Up to Week 16: Moderate | 18 | 18 |
| Up to Week 16: Severe | 2 | 0 |
| Up to Week 48: Mild | 57 | 57 |
| Up to Week 48: Moderate | 40 | 36 |
| Up to Week 48: Severe | 6 | 0 |
Hematology (Hemoglobin, Hematocrit, Erythrocyte, Lymphocyte/Leukocyte, Neutrophil/Leukocyte \<0.8\*Lower limit of normal (LLN), Reticulocyte \>1.5\*Upper limit of normal (ULN), Erythrocyte Mean Corpuscular Volume, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular HGB Concentration \<0.9\*LLN, \>1.1\*ULN, Reticulocyte/Erythrocyte, Leukocyte \>1.5\*ULN, Lymphocyte, Neutrophil \<0.8\*LLN and \>1.2\*ULN, Basophil, Basophil/Leukocyte, Eosinophil, Eosinophil/Leukocyte, Monocyte, Monocyte/Leukocyte \>1.2\*ULN); Clinical Chemistry (Bilirubin, Glucose \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase \>3.0\*ULN, Urea, Creatinine, Triglyceride, Cholesterol \>1.3\*ULN, LDL Cholesterol\>1.2\*ULN, Potassium, C Reactive Protein \>1.1\*ULN, Bicarbonate \<0.9\*LLN, Creatine Kinase \>2.0\*ULN, HDL Cholesterol \<0.8\*LLN), Urinalysis (Specific Gravity \>1.035, pH \>8, Glucose, Ketones, Protein, Hemoglobin \>=1, Erythrocyte, Leukocyte \>=20, Granular Cast, Hyaline Cast\>1.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Up to Week 16 | 106 | 129 |
| Up to Week 48 | 126 | 131 |
Criteria for abnormalities in vital signs: Pulse rate \<40 beats per minute (bpm) to \>120 bpm, Sitting Diastolic blood pressure \< 50 millimeter of mercury (mmHg), increase and decrease in change from baseline of \>= 20mmHg, sitting systolic blood pressure \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Up to Week 16, Pulse rate: <40 bpm | 0 | 0 |
| Up to Week 16, Pulse rate: >120 bpm | 0 | 0 |
| Up to Week 16, Sitting diastolic blood pressure: <50 mmHg | 0 | 0 |
| Up to Week 16, Sitting diastolic blood pressure: Change >= 20mmHg increase | 2 | 4 |
| Up to Week 16, Sitting diastolic blood pressure: Change >= 20mmHg decrease | 6 | 4 |
| Up to Week 16, Sitting systolic blood pressure: <90mmHg | 1 | 0 |
| Up to Week 16, Sitting systolic blood pressure: Change >= 30mmHg increase | 2 | 4 |
| Up to Week 16, Sitting systolic blood pressure: Change >= 30mmHg decrease | 2 | 5 |
| Up to Week 48, Pulse rate: <40 bpm | 0 | 0 |
| Up to Week 48, Pulse rate: >120 bpm | 0 | 1 |
| Up to Week 48, Sitting diastolic blood pressure: <50 mmHg | 0 | 0 |
| Up to Week 48, Sitting diastolic blood pressure: Change >= 20mmHg increase | 5 | 8 |
| Up to Week 48, Sitting diastolic blood pressure: Change >= 20mmHg decrease | 11 | 8 |
| Up to Week 48, Sitting systolic blood pressure: <90mmHg | 1 | 0 |
| Up to Week 48, Sitting systolic blood pressure: Change >= 30mmHg increase | 5 | 5 |
| Up to Week 48, Sitting systolic blood pressure: Change >= 30mmHg decrease | 5 | 7 |
Complete physical examination: included general appearance, skin (presence of rash), heent (head, eyes, ears, nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), lower extremities (presence of peripheral edema), abdominal (palpation and auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Abnormalities in physical examination was based on investigator's discretion/clinical judgement.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Abdomen: Screening | 2 | 1 |
| Abdomen: Week 16 | 1 | 2 |
| Abdomen: Week 48 | 1 | 1 |
| Extremities: Screening | 17 | 15 |
| Extremities: Week 16 | 8 | 14 |
| Extremities: Week 48 | 4 | 7 |
| General appearance: Screening | 10 | 11 |
| General appearance: Week 16 | 9 | 9 |
| General appearance: Week 48 | 7 | 6 |
| Head, eyes, ears, nose, throat: Screening | 5 | 7 |
| Head, eyes, ears, nose, throat: Week 16 | 4 | 7 |
| Head, eyes, ears, nose, throat: Week 48 | 3 | 7 |
| Heart: Screening | 2 | 2 |
| Heart: Week 16 | 0 | 2 |
| Heart: Week 48 | 0 | 2 |
| Lungs: Screening | 1 | 0 |
| Lungs: Week 16 | 0 | 0 |
| Lungs: Week 48 | 0 | 0 |
| Lymph nodes: Screening | 2 | 3 |
| Lymph nodes: Week 16 | 1 | 2 |
| Lymph nodes: Week 48 | 1 | 2 |
| Neurological: Screening | 4 | 0 |
| Neurological: Week 16 | 1 | 0 |
| Neurological: Week 48 | 2 | 0 |
| Skin: Screening | 18 | 18 |
| Skin: Week 16 | 14 | 13 |
| Skin: Week 48 | 12 | 12 |
Twelve-lead electrocardiograms (ECGs) were obtained for all participants. Criteria for ECG abnormality: PR interval \>=300 and a percent change from baseline of \>=25 or 50%; QRS duration \>=140 and a percent change from baseline of \>=50%; QT interval \>=500; QTCB, QTCF interval \<480 or \>=450, \<500 or \>=480, \>=500, change from baseline of \<60 and \>=30, and change from baseline of \>=60.
| Participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Up to Week 16, PR interval: >=300 | 0 | 0 |
| Up to Week 16, PR interval: %Change>=25/50% | 0 | 1 |
| Up to Week 16, QRS duration: >=140 | 1 | 1 |
| Up to Week 16, QRS duration: %Change>=50% | 0 | 0 |
| Up to Week 16, QT interval: >=500 | 0 | 0 |
| Up to Week 16, QTCB interval: >=450 and <480 | 3 | 7 |
| Up to Week 16, QTCB interval: >=480 and <500 | 0 | 1 |
| Up to Week 16, QTCB interval: >=500 | 0 | 0 |
| Up to Week 16, QTCB interval: change >=30 and <60 | 9 | 7 |
| Up to Week 16, QTCB interval: change >=60 | 0 | 0 |
| Up to Week 16, QTCF interval: >=450 and <480 | 3 | 4 |
| Up to Week 16, QTCF interval: >=480 and <500 | 0 | 0 |
| Up to Week 16, QTCF interval: >=500 | 0 | 0 |
| Up to Week 16, QTCF interval: change >=30 and <60 | 5 | 3 |
| Up to Week 16, QTCF interval: change >=60 | 0 | 0 |
| Up to Week 48, PR interval: >=300 | 0 | 0 |
| Up to Week 48, PR interval: %Change>=25/50% | 0 | 1 |
| Up to Week 48, QRS duration: >=140 | 3 | 1 |
| Up to Week 48, QRS duration: %Change>=50% | 0 | 0 |
| Up to Week 48, QT interval: >=500 | 0 | 1 |
| Up to Week 48, QTCB interval: >=450 and <480 | 10 | 10 |
| Up to Week 48, QTCB interval: >=480 and <500 | 1 | 1 |
| Up to Week 48, QTCB interval: >=500 | 0 | 0 |
| Up to Week 48, QTCB interval: change >=30 and <60 | 14 | 11 |
| Up to Week 48, QTCB interval: change >=60 | 1 | 0 |
| Up to Week 48, QTCF interval: >=450 and <480 | 5 | 5 |
| Up to Week 48, QTCF interval: >=480 and <500 | 1 | 0 |
| Up to Week 48, QTCF interval: >=500 | 0 | 0 |
| Up to Week 48, QTCF interval: change >=30 and <60 | 9 | 7 |
| Up to Week 48, QTCF interval: change >=60 | 1 | 0 |
ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 28.57 | 10.29 |
| Week 4 | 51.13 | 19.85 |
| Week 8 | 57.14 | 25.00 |
| Week 12 | 63.91 | 29.41 |
| Week 24 | 63.16 | 59.56 |
| Week 32 | 68.42 | 64.71 |
| Week 40 | 68.42 | 66.91 |
| Week 48 | 65.41 | 60.29 |
ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 10.53 | 4.41 |
| Week 4 | 27.07 | 3.68 |
| Week 8 | 34.59 | 5.88 |
| Week 12 | 42.86 | 11.76 |
| Week 24 | 48.12 | 41.91 |
| Week 32 | 50.38 | 44.12 |
| Week 40 | 50.38 | 42.65 |
| Week 48 | 50.38 | 44.85 |
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and calculated by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(high sensitivity \[hs\] CRP mg/Liter \[L\] + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -0.88 ± 0.056 | -0.17 ± 0.056 |
| Week 4 | -1.14 ± 0.065 | -0.24 ± 0.065 |
| Week 8 | -1.30 ± 0.074 | -0.24 ± 0.074 |
| Week 12 | -1.38 ± 0.075 | -0.28 ± 0.075 |
| Week 16 | -1.36 ± 0.073 | -0.39 ± 0.073 |
| Week 24 | -1.51 ± 0.082 | -1.32 ± 0.081 |
| Week 32 | -1.56 ± 0.084 | -1.37 ± 0.084 |
| Week 40 | -1.65 ± 0.086 | -1.40 ± 0.086 |
| week 48 | -1.70 ± 0.087 | -1.50 ± 0.086 |
Blood samples were collected for analysis of hsCRP using an assay analyzed by central laboratory. hsCRP is an acute phase reactant, which was indicative of inflammation and of its severity.
| Milligrams per deciliter (mg/dL) | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.07 ± 0.089 | -0.14 ± 0.088 |
| Week 4 | -1.06 ± 0.094 | -0.14 ± 0.094 |
| Week 8 | -1.05 ± 0.153 | -0.03 ± 0.152 |
| Week 12 | -1.11 ± 0.089 | -0.15 ± 0.090 |
| Week 16 | -1.05 ± 0.096 | -0.09 ± 0.096 |
| Week 24 | -1.21 ± 0.058 | -1.16 ± 0.058 |
| Week 32 | -1.16 ± 0.076 | -1.08 ± 0.075 |
| Week 40 | -1.22 ± 0.089 | -1.09 ± 0.089 |
| Week 48 | -1.17 ± 0.081 | -1.11 ± 0.080 |
The ASQoL was an 18-item questionnaire assessed the amount of restriction participant experienced in daily activities, level of pain and fatigue, and the impact on the participant's emotional state. Each item was scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranged from 0 (no impact) to 18 (yes-impact), with higher values indicated more impaired health-related quality of life.
| Units on scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | -4.03 ± 0.404 | -2.01 ± 0.405 |
| Week 48 | -5.97 ± 0.454 | -4.70 ± 0.451 |
SF-36 v.2 (Acute): 36-item generic health status measure. It measured 8 general health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, mental health. These domains were aggregated into 2 summary scores - physical component summary (PCS), mental component summary (MCS). Four domains comprised PCS score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised MCS score (vitality, social functioning, role-emotional, mental health). Normalized domain scores, PCS, MCS scores are used in analyses. Component and domain scores were scored by using United States 1998 general population norm. Resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scale and component summary measures had means of 50 and standard deviations of 10. Higher PCS/MCS/domain score represent better health status.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16: Physical Functioning | 5.52 ± 0.665 | 3.29 ± 0.665 |
| Week 16: Role-Physical | 6.13 ± 0.744 | 3.13 ± 0.745 |
| Week 16: Bodily Pain | 7.93 ± 0.710 | 3.47 ± 0.713 |
| Week 16: General Health | 5.00 ± 0.617 | 1.76 ± 0.618 |
| Week 16: Vitality | 5.34 ± 0.864 | 3.56 ± 0.869 |
| Week 16: Social Functioning | 5.45 ± 0.835 | 2.49 ± 0.837 |
| Week 16: Role-Emotional | 4.13 ± 1.020 | 2.05 ± 1.017 |
| Week 16: Mental Health | 3.57 ± 0.886 | 2.49 ± 0.888 |
| Week 16: Physical Component Summary | 6.69 ± 0.588 | 3.14 ± 0.590 |
| Week 16: Mental Component Summary | 3.45 ± 0.914 | 2.13 ± 0.915 |
| Week 48: Physical Functioning | 7.80 ± 0.775 | 6.94 ± 0.766 |
| Week 48: Role-Physical | 8.66 ± 0.870 | 7.29 ± 0.862 |
| Week 48: Bodily Pain | 11.67 ± 0.920 | 9.55 ± 0.912 |
| Week 48: General Health | 6.31 ± 0.777 | 5.10 ± 0.770 |
| Week 48: Vitality | 9.83 ± 0.997 | 9.28 ± 0.992 |
| Week 48: Social Functioning | 8.16 ± 0.923 | 6.77 ± 0.915 |
| Week 48: Role-Emotional | 7.17 ± 1.004 | 6.32 ± 0.989 |
| Week 48: Mental Health | 7.10 ± 0.960 | 6.45 ± 0.954 |
| Week 48: Physical Component Summary | 8.81 ± 0.720 | 7.39 ± 0.714 |
| Week 48: Mental Component Summary | 7.07 ± 0.926 | 6.35 ± 0.920 |
BASMI assess axial status and spinal mobility. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component score mapped between 0 and 10, high score=more impairment of axial status, spinal mobility. For cervical rotation angle, participant sit straight on chair with chin level and hands on knees. Blinded assessor place goniometer at top of head in line with nose and ask participant to rotate neck maximally to left, follows with goniometer and record angle between sagittal plane and new plane after rotation. A second reading obtained and both readings recorded. Procedure repeated for right side. Better of two for each side was selected for scoring. Scoring done by calculating mean of left and right measurement and recorded in degrees (range: 0 to 90), higher cervical rotation value=better health status.
| Degrees | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 2.25 ± 0.701 | 0.95 ± 0.698 |
| Week 4 | 3.63 ± 0.797 | 2.07 ± 0.792 |
| Week 8 | 6.26 ± 0.825 | 2.44 ± 0.824 |
| Week 12 | 6.24 ± 1.002 | 2.92 ± 1.004 |
| Week 16 | 7.74 ± 1.009 | 3.00 ± 1.008 |
| Week 24 | 7.68 ± 1.139 | 7.49 ± 1.131 |
| Week 32 | 7.25 ± 1.087 | 8.23 ± 1.080 |
| Week 40 | 7.62 ± 1.215 | 8.34 ± 1.207 |
| Week 48 | 7.63 ± 1.201 | 8.23 ± 1.188 |
BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of intermalleolar distances, participant should lie supine with the knees straight and feet/toes pointing straight up and asked to separate the legs as far as possible and the distance between the medial malleoli was measured (in Centimeters \[cm\] to the nearest 0.1 cm). Distance (in cm) was greater than or equal to 0, with no maximum defined range: higher intermalleolar distance value indicates better health status.
| Centimeters | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 2.29 ± 0.733 | 0.90 ± 0.730 |
| Week 4 | 3.62 ± 0.861 | 0.84 ± 0.856 |
| Week 8 | 4.68 ± 0.979 | 1.36 ± 0.976 |
| Week 12 | 5.33 ± 1.106 | 1.97 ± 1.108 |
| Week 16 | 6.84 ± 1.084 | 2.64 ± 1.082 |
| Week 24 | 7.79 ± 1.177 | 4.39 ± 1.174 |
| Week 32 | 8.98 ± 1.221 | 5.32 ± 1.215 |
| Week 40 | 8.60 ± 1.229 | 4.75 ± 1.222 |
| Week 48 | 7.83 ± 1.233 | 4.34 ± 1.222 |
BASMI assess axial status, spinal mobility, using linear function. It composed of 5 clinical measures. BASMI - Linear Method score-average of 5 component scores mapped between 0 and 10, with high scores =more impairment of axial status, spinal mobility. For assessment of lateral spinal flexion: participant stand upright with head and back rest against wall as close as possible with shoulders level and feet 30 cm apart and feet parallel. At tip of middle finger, place a mark on thigh. This neutral position recorded. Participant bend sideways without bending knees or lifting heels while attempting to keep shoulders in same position (flexion position). Second mark placed, lateral flexion recorded (left or right as appropriate) using cm tape measure. Two tries for left, two tries for right measured. Result of two tries recorded for left and right separately in cm to nearest 0.1 cm. Distance (in cm) should be \>=0, with no maximum defined range: high value indicates better health status.
| Centimeters | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 0.60 ± 0.200 | -0.21 ± 0.199 |
| Week 4 | 0.96 ± 0.235 | -0.10 ± 0.233 |
| Week 8 | 1.34 ± 0.238 | 0.15 ± 0.237 |
| Week 12 | 1.42 ± 0.214 | -0.21 ± 0.214 |
| Week 16 | 1.79 ± 0.269 | -0.08 ± 0.269 |
| Week 24 | 1.70 ± 0.278 | 0.75 ± 0.276 |
| Week 32 | 1.90 ± 0.319 | 1.31 ± 0.316 |
| Week 40 | 2.15 ± 0.332 | 1.37 ± 0.329 |
| Week 48 | 1.64 ± 0.345 | 1.34 ± 0.340 |
BASMI assessed axial status and spinal mobility. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of lumbar flexion, With the participant standing erect and outer edges of feet 30 cm apart, a mark was placed in the midpoint of a line that joins the posterior superior iliac spines (baseline mark). A second mark (A) was placed 10 cm above the baseline mark and a third mark (B) 5 cm below the baseline mark. Then have the participant maximally bend forward, keeping the knees fully extended. With the participant's spine in full flexion, the distance between marks A and B (in cm to the nearest 0.1 cm) was re-measured. Distance (in cm) was greater than or equal to 0, with no maximum defined range. Higher value indicates better health status.
| Centimeters | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 0.30 ± 0.102 | -0.07 ± 0.102 |
| Week 4 | 0.41 ± 0.102 | -0.11 ± 0.102 |
| Week 8 | 0.32 ± 0.116 | -0.17 ± 0.115 |
| Week 12 | 0.26 ± 0.111 | -0.22 ± 0.111 |
| Week 16 | 0.46 ± 0.115 | -0.06 ± 0.115 |
| Week 24 | 0.51 ± 0.149 | 0.20 ± 0.148 |
| Week 32 | 0.64 ± 0.143 | 0.39 ± 0.142 |
| Week 40 | 0.58 ± 0.156 | 0.50 ± 0.155 |
| Week 48 | 0.45 ± 0.146 | 0.35 ± 0.144 |
BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of tragus-to-wall distance, participant was placed standing with his/her back against the wall; knees straight; scapulae, buttocks, and heels against wall; and head in as neutral position as possible. The distance between the tragus and wall in cm was measured (to the nearest 0.1 cm) from both the right side and left side at the maximum effort to touch the head against the wall. Distance should be greater than or equal to 0 cm with no defined maximum value, lower tragus-to-wall value indicates better health status.
| Centimeters | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -0.19 ± 0.126 | -0.24 ± 0.125 |
| Week 4 | -0.48 ± 0.144 | -0.07 ± 0.143 |
| Week 8 | -0.51 ± 0.177 | 0.36 ± 0.177 |
| Week 12 | -0.40 ± 0.169 | 0.23 ± 0.169 |
| Week 16 | -0.50 ± 0.168 | 0.09 ± 0.168 |
| Week 24 | -0.66 ± 0.202 | -0.03 ± 0.201 |
| Week 32 | -0.66 ± 0.179 | 0.00 ± 0.178 |
| Week 40 | -0.60 ± 0.200 | -0.14 ± 0.199 |
| Week 48 | -0.73 ± 0.204 | -0.18 ± 0.202 |
The BASMI was used to assess the axial status and spinal mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue) and was analyzed using the linear function method. BASMI score composed of five clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation. BASMI - Linear Method score was the average of 5 individual component scores mapped between 0 and 10 and thus the BASMI - Linear Method total score ranged from 0 (very good) to 10 (very poor), wherein higher scores indicated more impairment of axial status and spinal mobility; lower scores indicated better health status.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -0.25 ± 0.044 | -0.03 ± 0.043 |
| Week 4 | -0.39 ± 0.053 | -0.06 ± 0.053 |
| Week 8 | -0.49 ± 0.059 | -0.03 ± 0.058 |
| Week 12 | -0.49 ± 0.058 | -0.02 ± 0.058 |
| Week 16 | -0.63 ± 0.060 | -0.11 ± 0.060 |
| Week 24 | -0.67 ± 0.068 | -0.38 ± 0.068 |
| Week 32 | -0.74 ± 0.069 | -0.52 ± 0.068 |
| Week 40 | -0.74 ± 0.074 | -0.55 ± 0.073 |
| Week 48 | -0.69 ± 0.074 | -0.54 ± 0.073 |
FACIT-F is a 13-item questionnaire (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired), with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three type of scores were derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score was calculated by summing the 13 items (range 0 \[not at all\] to 52 \[very much\]); higher scores represent less fatigue status. In this outcome measure, change from baseline in FACIT-F total score was reported.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 3.16 ± 0.552 | 0.32 ± 0.548 |
| Week 4 | 4.80 ± 0.595 | 1.19 ± 0.591 |
| Week 8 | 6.46 ± 0.706 | 1.03 ± 0.703 |
| Week 12 | 6.25 ± 0.737 | 1.24 ± 0.736 |
| Week 16 | 6.54 ± 0.795 | 3.12 ± 0.794 |
| Week 24 | 7.42 ± 0.842 | 5.84 ± 0.836 |
| Week 32 | 7.90 ± 0.813 | 7.24 ± 0.807 |
| Week 40 | 8.67 ± 0.817 | 7.15 ± 0.810 |
| Week 48 | 9.54 ± 0.897 | 7.35 ± 0.891 |
FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score was calculated by summing 5 items: I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy. FACIT-F total experience domain score ranged from 0 (not at all) to 20 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F experience domain score was reported.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 1.35 ± 0.275 | 0.11 ± 0.274 |
| Week 4 | 2.30 ± 0.298 | 0.60 ± 0.296 |
| Week 8 | 2.72 ± 0.331 | 0.53 ± 0.330 |
| Week 12 | 2.78 ± 0.343 | 0.80 ± 0.344 |
| Week 16 | 2.85 ± 0.357 | 1.29 ± 0.357 |
| Week 24 | 3.58 ± 0.384 | 2.96 ± 0.382 |
| Week 32 | 3.65 ± 0.370 | 3.43 ± 0.367 |
| Week 40 | 3.98 ± 0.375 | 3.59 ± 0.371 |
| Week 48 | 4.22 ± 0.403 | 3.40 ± 0.400 |
FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless, I feel tired, and I have energy, while FACIT-F impact domain score was calculated by summing the remaining 8 items. FACIT-F impact domain score ranged from 0 (not at all) to 32 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F impact domain score was reported.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 1.79 ± 0.334 | 0.17 ± 0.332 |
| Week 4 | 2.47 ± 0.364 | 0.55 ± 0.361 |
| Week 8 | 3.73 ± 0.429 | 0.46 ± 0.428 |
| Week 12 | 3.45 ± 0.440 | 0.41 ± 0.441 |
| Week 16 | 3.68 ± 0.488 | 1.81 ± 0.487 |
| Week 24 | 3.84 ± 0.504 | 2.86 ± 0.501 |
| Week 32 | 4.25 ± 0.489 | 3.80 ± 0.485 |
| Week 40 | 4.70 ± 0.480 | 3.57 ± 0.476 |
| Week 48 | 5.32 ± 0.542 | 3.95 ± 0.538 |
Participants answered the question, "How active was your spondylitis on average during the last week?. Participant's response was recorded using a numerical rating scale ranged from 0 (Not Active) to 10 (Very Active), with higher scores indicated more severe disease.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.21 ± 0.144 | -0.32 ± 0.144 |
| Week 4 | -1.85 ± 0.168 | -0.63 ± 0.167 |
| Week 8 | -2.14 ± 0.181 | -0.42 ± 0.181 |
| Week 12 | -2.37 ± 0.193 | -0.65 ± 0.193 |
| Week 16 | -2.47 ± 0.204 | -0.91 ± 0.204 |
| Week 24 | -2.76 ± 0.222 | -2.21 ± 0.221 |
| Week 32 | -3.04 ± 0.228 | -2.43 ± 0.226 |
| Week 40 | -3.04 ± 0.222 | -2.50 ± 0.220 |
| Week 48 | -3.47 ± 0.225 | -2.94 ± 0.223 |
Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.28 ± 0.145 | -0.38 ± 0.144 |
| Week 4 | -2.05 ± 0.164 | -0.71 ± 0.164 |
| Week 8 | -2.51 ± 0.173 | -0.53 ± 0.173 |
| Week 12 | -2.57 ± 0.192 | -0.69 ± 0.192 |
| Week 16 | -2.57 ± 0.191 | -0.96 ± 0.191 |
| Week 24 | -2.99 ± 0.206 | -2.47 ± 0.205 |
| Week 32 | -3.16 ± 0.212 | -2.86 ± 0.210 |
| Week 40 | -3.11 ± 0.217 | -2.62 ± 0.215 |
| Week 48 | -3.57 ± 0.220 | -2.87 ± 0.218 |
Participants marked their level of nocturnal spinal pain on a NRS ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.24 ± 0.162 | -0.32 ± 0.161 |
| Week 4 | -2.15 ± 0.169 | -0.56 ± 0.167 |
| Week 8 | -2.61 ± 0.191 | -0.59 ± 0.190 |
| Week 12 | -2.60 ± 0.198 | -0.60 ± 0.199 |
| Week 16 | -2.67 ± 0.204 | -0.84 ± 0.204 |
| Week 24 | -3.07 ± 0.217 | -2.59 ± 0.215 |
| Week 32 | -3.17 ± 0.219 | -2.89 ± 0.217 |
| Week 40 | -3.20 ± 0.226 | -2.73 ± 0.224 |
| Week 48 | -3.52 ± 0.229 | -3.01 ± 0.227 |
BASFI was a functional index which included 10 items assessing ability of participants to perform normal daily activities. The first 8 questions/items consider activities related to functional anatomy. The final 2 questions/items assess the participants' ability to cope with everyday life. Each item was scored on a scale of 0=easy to 10=impossible. The BASFI total score was calculated as the average score of these 10 individual items. BASFI total score ranged from 0 (easy) to 10 (impossible), where higher scores indicated more severe disease activity.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -0.87 ± 0.125 | -0.45 ± 0.124 |
| Week 4 | -1.35 ± 0.140 | -0.58 ± 0.139 |
| Week 8 | -1.79 ± 0.158 | -0.69 ± 0.157 |
| Week 12 | -2.01 ± 0.164 | -0.71 ± 0.164 |
| Week 16 | -2.05 ± 0.170 | -0.82 ± 0.169 |
| Week 24 | -2.25 ± 0.191 | -1.91 ± 0.190 |
| Week 32 | -2.42 ± 0.188 | -2.16 ± 0.187 |
| Week 40 | -2.62 ± 0.192 | -2.23 ± 0.191 |
| Week 48 | -2.61 ± 0.196 | -2.32 ± 0.195 |
The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI inflammation score was derived by taking mean of the responses of question 5 and 6 and ranged from 0 (none) to 10 (very severe), where higher score indicated more inflammation (morning stiffness).
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.33 ± 0.149 | -0.49 ± 0.149 |
| Week 4 | -2.08 ± 0.164 | -0.60 ± 0.163 |
| Week 8 | -2.52 ± 0.178 | -0.91 ± 0.178 |
| Week 12 | -2.71 ± 0.185 | -0.84 ± 0.186 |
| Week 16 | -2.69 ± 0.185 | -0.97 ± 0.185 |
| Week 24 | -2.99 ± 0.193 | -2.48 ± 0.193 |
| Week 32 | -3.11 ± 0.200 | -2.61 ± 0.199 |
| Week 40 | -3.28 ± 0.204 | -2.64 ± 0.203 |
| Week 48 | -3.46 ± 0.214 | -2.90 ± 0.213 |
ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 16.54 | 2.94 |
| Week 4 | 35.34 | 6.62 |
| Week 8 | 41.35 | 8.09 |
| Week 12 | 45.86 | 9.56 |
| Week 16 | 43.61 | 7.35 |
| Week 24 | 49.62 | 44.12 |
| Week 32 | 51.13 | 53.68 |
| Week 40 | 48.87 | 50.74 |
| Week 48 | 43.61 | 44.85 |
Partial remission was defined as a score of 2 or less (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains in ASAS. These 4 domains included: PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 2.26 | 0 |
| Week 4 | 4.51 | 0 |
| Week 8 | 7.52 | 1.47 |
| Week 12 | 15.04 | 2.94 |
| Week 16 | 15.04 | 2.94 |
| Week 24 | 21.80 | 11.76 |
| Week 32 | 23.31 | 15.44 |
| Week 40 | 24.06 | 16.91 |
| Week 48 | 23.31 | 17.65 |
The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.25 ± 0.127 | -0.52 ± 0.126 |
| Week 4 | -1.95 ± 0.146 | -0.67 ± 0.145 |
| Week 8 | -2.32 ± 0.164 | -0.82 ± 0.163 |
| Week 12 | -2.49 ± 0.172 | -0.81 ± 0.172 |
| Week 16 | -2.55 ± 0.175 | -1.11 ± 0.174 |
| Week 24 | -2.81 ± 0.185 | -2.41 ± 0.184 |
| Week 32 | -2.94 ± 0.191 | -2.53 ± 0.190 |
| Week 40 | -3.09 ± 0.193 | -2.63 ± 0.192 |
| Week 48 | -3.30 ± 0.199 | -2.80 ± 0.197 |
BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. BASDAI score was calculated by computing mean of questions 5 and 6 and adding it to sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI50 response was defined as decrease of \>=50% from Baseline in BASDAI score at specified time points. Percentage of participants with BASDAI 50 response at specified weeks are reported.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 12.03 | 3.68 |
| Week 4 | 29.32 | 6.62 |
| Week 8 | 39.85 | 11.03 |
| Week 12 | 42.86 | 11.03 |
| Week 16 | 42.86 | 17.65 |
| Week 24 | 47.37 | 36.76 |
| Week 32 | 51.13 | 41.18 |
| Week 40 | 52.63 | 39.71 |
| Week 48 | 51.13 | 40.44 |
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) clinically important improvement was defined as decrease from Baseline of \>=1.1 units in ASDAS(CRP) score.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 39.39 | 6.62 |
| Week 4 | 53.03 | 12.50 |
| Week 8 | 59.85 | 14.71 |
| Week 12 | 60.61 | 15.44 |
| Week 16 | 61.36 | 19.12 |
| Week 24 | 65.15 | 60.29 |
| Week 32 | 65.91 | 61.76 |
| Week 40 | 63.64 | 57.35 |
| Week 48 | 58.33 | 52.94 |
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) major improvement was defined as a response if improvement (decrease) from Baseline in ASDAS(CRP) of \>=2.0 units.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 8.94 | 0.00 |
| Week 4 | 17.89 | 1.55 |
| Week 8 | 22.76 | 2.33 |
| Week 12 | 26.02 | 3.10 |
| Week 16 | 30.08 | 4.65 |
| Week 24 | 34.15 | 24.81 |
| Week 32 | 36.59 | 34.11 |
| Week 40 | 39.02 | 31.78 |
| Week 48 | 33.33 | 28.68 |
ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) inactive disease is defined as a response if actual ASDAS(CRP) was \<1.3 units.
| Percentage of participants | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 0.75 | 0.00 |
| Week 4 | 3.76 | 0.00 |
| Week 8 | 6.02 | 0.74 |
| Week 12 | 11.28 | 0.74 |
| Week 16 | 6.77 | 0.00 |
| Week 24 | 12.78 | 11.76 |
| Week 32 | 18.05 | 13.24 |
| Week 40 | 17.29 | 16.91 |
| Week 48 | 15.04 | 13.24 |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Sites assessed included 1st costochondral joint (left \[l\]/right \[r\]), 7th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES score ranging from 0 (no tenderness) to 13 (worst possible score) with higher score indicated more severe tenderness.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 4 | -1.42 ± 0.264 | -0.59 ± 0.244 |
| Week 8 | -2.02 ± 0.275 | -1.28 ± 0.255 |
| Week 12 | -1.89 ± 0.289 | -1.17 ± 0.271 |
| Week 16 | -1.94 ± 0.288 | -1.41 ± 0.272 |
| Week 24 | -2.50 ± 0.251 | -2.32 ± 0.240 |
| Week 32 | -2.73 ± 0.204 | -2.54 ± 0.200 |
| Week 40 | -2.73 ± 0.189 | -2.75 ± 0.183 |
| Week 48 | -2.87 ± 0.225 | -2.56 ± 0.222 |
Swollen joint count was an assessment on 44 joints (sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals, thumb interphalangeal, proximal interphalangeals, knees, ankles, and metatarsophalangeals). Each joint was assessed for swelling as: Present or Absent. Artificial joints were not assessed
| Joint count | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | -1.71 ± 0.376 | -2.09 ± 0.358 |
| Week 4 | -1.90 ± 0.418 | -2.23 ± 0.398 |
| Week 8 | -2.39 ± 0.456 | -2.45 ± 0.438 |
| Week 12 | -2.79 ± 0.428 | -2.45 ± 0.419 |
| Week 16 | -3.35 ± 0.475 | -2.79 ± 0.465 |
| Week 24 | -2.81 ± 0.346 | -3.32 ± 0.335 |
| Week 32 | -2.45 ± 0.357 | -3.21 ± 0.341 |
| Week 40 | -3.04 ± 0.289 | -3.34 ± 0.274 |
| Week 48 | -3.31 ± 0.176 | -3.82 ± 0.174 |
Chest expansion (measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion which was defined to be greater than or equal to 0 cm with no defined maximum/upper limit. Greater chest circumference corresponds to higher score indicated more spinal mobility/better health status (measured as Chest Expansion in cm).
| Centimeter | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 2 | 0.22 ± 0.084 | -0.09 ± 0.083 |
| Week 4 | 0.25 ± 0.094 | -0.07 ± 0.094 |
| Week 8 | 0.46 ± 0.114 | 0.22 ± 0.114 |
| Week 12 | 0.57 ± 0.102 | 0.25 ± 0.102 |
| Week 16 | 0.59 ± 0.128 | 0.38 ± 0.127 |
| Week 24 | 0.62 ± 0.133 | 0.63 ± 0.132 |
| Week 32 | 0.61 ± 0.149 | 0.71 ± 0.148 |
| Week 40 | 0.75 ± 0.132 | 0.68 ± 0.131 |
| Week 48 | 0.50 ± 0.127 | 0.47 ± 0.125 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Participants rated 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The mean of the summed score ranged from 1 to 3 with "1" corresponding to no problems and "3" corresponding to severe problems in the 5 dimensions, where higher score indicates more severe problems.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16: Mobility | -0.23 ± 0.044 | -0.06 ± 0.044 |
| Week 16: Self-Care | -0.21 ± 0.043 | -0.20 ± 0.043 |
| Week 16: Usual Activities | -0.18 ± 0.046 | -0.09 ± 0.046 |
| Week 16: Pain/Discomfort | -0.30 ± 0.036 | -0.12 ± 0.036 |
| Week 16: Anxiety/Depression | -0.11 ± 0.048 | -0.10 ± 0.048 |
| Week 48: Mobility | -0.32 ± 0.051 | -0.26 ± 0.050 |
| Week 48: Self-Care | -0.33 ± 0.048 | -0.33 ± 0.047 |
| Week 48: Usual Activities | -0.32 ± 0.053 | -0.34 ± 0.053 |
| Week 48: Pain/Discomfort | -0.37 ± 0.047 | -0.36 ± 0.047 |
| Week 48: Anxiety/Depression | -0.17 ± 0.054 | -0.21 ± 0.053 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Its second part included EQ-VAS. EQ-VAS recorded the participant's self-rated health on a VAS ranging from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state), with higher scores indicating better health state.
| Millimeter (mm) | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | 13.00 ± 1.840 | 2.89 ± 1.840 |
| Week 48 | 20.64 ± 1.879 | 18.00 ± 1.862 |
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent work time missed due to health problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | -3.65 ± 2.659 | 0.88 ± 2.622 |
| Week 48 | -8.10 ± 2.136 | -5.79 ± 2.047 |
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent Impairment while Working due to Health Problem was a subscale and calculated as: Q5/10 for those who were currently employed and actually worked in the past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | -19.83 ± 2.274 | -6.94 ± 2.303 |
| Week 48 | -25.35 ± 2.769 | -23.00 ± 2.656 |
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent overall work impairment due to health problem was a subscale and calculated as: Q2/(Q2+Q4)+\[(1- Q2/(Q2+Q4))×(Q5/10)\] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | -21.49 ± 2.508 | -7.64 ± 2.559 |
| Week 48 | -27.63 ± 3.005 | -23.22 ± 2.890 |
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent activity impairment due to health problem was a subscale and calculated as: Q6/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.
| Units on a scale | Tofacitinib | Placebo Then Tofacitinib |
|---|---|---|
| Week 16 | -19.03 ± 1.969 | -5.63 ± 1.968 |
| Week 48 | -27.37 ± 2.339 | -19.77 ± 2.310 |
Collected over For the first 2 arms: (tofacitinib and Placebo [up to Week 16]): Baseline to Week 16 and for the next 2 arms (tofacitinib and placebo then tofacitinib [Day 1 to Week 48]): Baseline to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib: Up to Week 16 | 0/133 (0%) | 2/133 (1.5%) | 23/133 (17.3%) |
| Placebo: Up to Week 16 | 0/136 (0%) | 1/136 (0.7%) | 26/136 (19.1%) |
| Tofacitinib: Day 1 to Week 48 | 0/133 (0%) | 7/133 (5.3%) | 51/133 (38.3%) |
| Placebo Then Tofacitinib: Day 1 to Week 48 | 0/136 (0%) | 2/136 (1.5%) | 52/136 (38.2%) |
| Event | Tofacitinib: Up to Week 16 | Placebo: Up to Week 16 | Tofacitinib: Day 1 to Week 48 | Placebo Then Tofacitinib: Day 1 to Week 48 |
|---|---|---|---|---|
| HypoacusisEar and labyrinth disorders | 1/133 | 0/136 | 1/133 | 0/136 |
| Abdominal adhesionsGastrointestinal disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| Meningitis asepticInfections and infestations | 1/133 | 0/136 | 1/133 | 0/136 |
| Rib fractureInjury, poisoning and procedural complications | 0/133 | 0/136 | 1/133 | 0/136 |
| MigraineNervous system disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| UreterolithiasisRenal and urinary disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| Subcutaneous emphysemaSkin and subcutaneous tissue disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| Hyperplastic cholecystopathyHepatobiliary disorders | 0/133 | 0/136 | 1/133 | 0/136 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/133 | 0/136 | 0/133 | 1/136 |
| Event | Tofacitinib: Up to Week 16 | Placebo: Up to Week 16 | Tofacitinib: Day 1 to Week 48 | Placebo Then Tofacitinib: Day 1 to Week 48 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/133 | 10/136 | 21/133 | 18/136 |
| NasopharyngitisInfections and infestations | 9/133 | 10/136 | 11/133 | 17/136 |
| DiarrhoeaGastrointestinal disorders | 0/133 | 0/136 | 10/133 | 8/136 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/133 | 8/136 | 2/133 | 9/136 |
| Alanine aminotransferase increasedInvestigations | 0/133 | 0/136 | 8/133 | 2/136 |
| Protein urine presentInvestigations | 0/133 | 0/136 | 8/133 | 4/136 |
| HeadacheNervous system disorders | 0/133 | 0/136 | 5/133 | 7/136 |
| Abdominal pain upperGastrointestinal disorders | 0/133 | 0/136 | 2/133 | 7/136 |
Safety analysis set: included all participants who were randomized and received at least one dose of the investigational product (that is \[i.e.\], tofacitinib or placebo).
| Age, Continuous(Years) | Tofacitinib | Placebo Then Tofacitinib | Total |
|---|---|---|---|
| Mean | 42.2 ± 11.85 | 40.0 ± 11.06 | 41.1 ± 11.49 |
| Sex: Female, Male(Participants) | Tofacitinib | Placebo Then Tofacitinib | Total |
|---|---|---|---|
| Female | 17 | 28 | 45 |
| Male | 116 | 108 | 224 |
| Race/Ethnicity, Customized(Participants) | Tofacitinib | Placebo Then Tofacitinib | Total |
|---|---|---|---|
| White | 107 | 106 | 213 |
| Asian | 25 | 30 | 55 |
| Not reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2018 to primary completion in Dec 2019, 18 months.
Results were first posted in Jan 2021, 1 year after primary completion.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 18 months is below that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib